Clinical Trials
2 trialsNCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT04139772 2023-03-24
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
National Cancer Institute, Naples
Phase 3 Unknown